Institution
University of Warwick
Education•Coventry, Warwickshire, United Kingdom•
About: University of Warwick is a education organization based out in Coventry, Warwickshire, United Kingdom. It is known for research contribution in the topics: Population & White dwarf. The organization has 26212 authors who have published 77127 publications receiving 2666552 citations. The organization is also known as: Warwick University & The University of Warwick.
Topics: Population, White dwarf, Politics, Health care, Poison control
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This work reviews the use of models in smallpox planning within the broader epidemiological context set by recent outbreaks of both novel and re-emerging pathogens.
Abstract: Mathematical models of viral transmission and control are important tools for assessing the threat posed by deliberate release of the smallpox virus and the best means of containing an outbreak. Models must balance biological realism against limitations of knowledge, and uncertainties need to be accurately communicated to policy-makers. Smallpox poses the particular challenge that key biological, social and spatial factors affecting disease spread in contemporary populations must be elucidated largely from historical studies undertaken before disease eradication in 1979. We review the use of models in smallpox planning within the broader epidemiological context set by recent outbreaks of both novel and re-emerging pathogens.
380 citations
••
TL;DR: Results indicated that the copper effect could explain a similar switch in intracellular location observed in Methylosinus trichosporium OB3b but that some methanotrophs do not have the capacity to overcome copper stress in this way.
Abstract: The intracellular location of methane mono-oxygenase (MMO) activity in the methanotroph Methylococcus capsulatus (Bath) has been shown to depend primarily on the availability of copper. MMO activity was observed in the particulate fraction of cell extracts under conditions of copper excess but switched to a soluble location in response to copper stress. The two activities could be differentiated by sensitivity to a range of inhibitors and by major changes in the polypeptide banding patterns on denaturing polyacrylamide gels. MMO activity concomitant with the oxidation of ethanol was only observed in cells with particulate MMO activity but could be lost independently in response to copper stress. Examination of other methanotrophs indicated that the copper effect could explain a similar switch in intracellular location observed in Methylosinus trichosporium OB3b but that some methanotrophs do not have the capacity to overcome copper stress in this way.
380 citations
••
TL;DR: High quality evidence is found that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation; the findings are dominated by the three largest trials.
Abstract: Background
Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women, however the results of randomised controlled trials (RCTs) have had mixed results. This is an updated version of a Cochrane review published in 2013.
Objectives
To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women, and whether there are differential effects between use in primary or secondary prevention.
Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (≥ 10 years versus < 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (≥ 60 years of age versus < 60 years of age); and (ii) assess the effects of length of time on treatment.
Search methods
We searched the following databases on 25 February 2014: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE and LILACS. We also searched research and trials registers, and conducted reference checking of relevant studies and related systematic reviews to identify additional studies.
Selection criteria
RCTs of women comparing orally administered hormone therapy with placebo or a no treatment control, with a minimum of six months follow-up.
Data collection and analysis
Two authors independently assessed study quality and extracted data. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for each outcome. We combined results using random effects meta-analyses, and undertook further analyses to assess the effects of treatment as primary or secondary prevention, and whether treatment was commenced more than or less than 10 years after menopause.
Main results
We identified six new trials through this update. Therefore the review includes 19 trials with a total of 40,410 post-menopausal women. On the whole, study quality was good and generally at low risk of bias; the findings are dominated by the three largest trials. We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation. However, there was an increased risk of stroke in those in the hormone therapy arm for combined primary and secondary prevention (RR 1.24, 95% CI 1.10 to 1.41). Venous thromboembolic events were increased (RR 1.92, 95% CI 1.36 to 2.69), as were pulmonary emboli (RR 1.81, 95% CI 1.32 to 2.48) on hormone therapy relative to placebo.
The absolute risk increase for stroke was 6 per 1000 women (number needed to treat for an additional harmful outcome (NNTH) = 165; mean length of follow-up: 4.21 years (range: 2.0 to 7.1)); for venous thromboembolism 8 per 1000 women (NNTH = 118; mean length of follow-up: 5.95 years (range: 1.0 to 7.1)); and for pulmonary embolism 4 per 1000 (NNTH = 242; mean length of follow-up: 3.13 years (range: 1.0 to 7.1)).
We performed subgroup analyses according to when treatment was started in relation to the menopause. Those who started hormone therapy less than 10 years after the menopause had lower mortality (RR 0.70, 95% CI 0.52 to 0.95, moderate quality evidence) and coronary heart disease (composite of death from cardiovascular causes and non-fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; moderate quality evidence), though they were still at increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73, high quality evidence) compared to placebo or no treatment. There was no strong evidence of effect on risk of stroke in this group. In those who started treatment more than 10 years after the menopause there was high quality evidence that it had little effect on death or coronary heart disease between groups but there was an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38, high quality evidence) and venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80, high quality evidence).
Authors' conclusions
Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events.
380 citations
•
Abstract: Based on the estimation of a theoretically consistent gravity equation, together with a careful computation of transportation costs across countries and industries, the Paper first provides estimates of 'border effects' among EU countries. The second objective is to examine the reasons for border effects. Contrarily to the previous findings reported in the literature, we show that national trade barriers do provide an explanation. In particular, technical barriers to trade, together with firm and product-specific information costs, increase border effects, whereas non-tariff barriers are not significant. Our results however suggest that these barriers are not the only cause since the spatial clustering of firms is also shown to matter.
379 citations
••
TL;DR: In this paper, the authors identify deep democratic deficits that have emerged as a consequence of contemporary globalisation and discuss various ways that civil society can either enhance or undermine democracy in the governance of global relations.
Abstract: Recent years have witnessed substantial civil society mobilisation on questions of global governance. This paper considers the implications of this development for democracy. After specifying concepts of ‘civil society’, ‘democracy’, ‘globality’ and ‘governance’, the paper identifies deep democratic deficits that have emerged as a consequence of contemporary globalisation. The discussion then outlines various ways that civil society can either enhance or undermine democracy in the governance of global relations.
379 citations
Authors
Showing all 26659 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Miller | 203 | 2573 | 204840 |
Daniel R. Weinberger | 177 | 879 | 128450 |
Kay-Tee Khaw | 174 | 1389 | 138782 |
Joseph E. Stiglitz | 164 | 1142 | 152469 |
Edmund T. Rolls | 153 | 612 | 77928 |
Thomas J. Smith | 140 | 1775 | 113919 |
Tim Jones | 135 | 1314 | 91422 |
Ian Ford | 134 | 678 | 85769 |
Paul Harrison | 133 | 1400 | 80539 |
Sinead Farrington | 133 | 1422 | 91099 |
Peter Hall | 132 | 1640 | 85019 |
Paul Brennan | 132 | 1221 | 72748 |
G. T. Jones | 131 | 864 | 75491 |
Peter Simmonds | 131 | 823 | 62953 |
Tim Martin | 129 | 878 | 82390 |